Parkman Healthcare Partners LLC Purchases Shares of 1,624,279 BioCryst Pharmaceuticals, Inc. $BCRX

Parkman Healthcare Partners LLC purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,624,279 shares of the biotechnology company’s stock, valued at approximately $16,243,000. BioCryst Pharmaceuticals makes up about 1.7% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 24th largest holding.

A number of other large investors have also modified their holdings of the stock. Bank of America Corp DE grew its position in shares of BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after buying an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $14,880,000. Wedge Capital Management L L P NC acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $3,808,000. Perceptive Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after purchasing an additional 4,271,504 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after purchasing an additional 482,494 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $9.68 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -6.45 and a beta of 0.56. The company has a 50-day simple moving average of $9.64 and a 200-day simple moving average of $8.97.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.15 EPS. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Cantor Fitzgerald lifted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.